Venetoclax plus chemotherapy for blastic dendritic cell cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Skin clinical trials.
This Phase 2 trial tests venetoclax combined with chemotherapy to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). It may help shrink BPDCN and control the disease, whether you’re newly diagnosed or the cancer has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have a confirmed BPDCN diagnosis (by a pathology report using WHO criteria).
- Your BPDCN is newly diagnosed (no prior treatment) or has relapsed after at least one prior treatment; sometimes 1 dose/cycle of BPDCN-directed therapy before enrollment is allowed.
- Your body can handle treatment: blood tests and liver/kidney numbers are within required limits, and your albumin is high enough.
- Your heart function is strong enough: your heart pumping strength (left ventricular ejection fraction) meets the study’s lower limit on an echo or MUGA scan within 30 days.
- You can do day-to-day activities at an acceptable level (ECOG 0–2).
- You can follow the visit schedule and sign informed consent; if you could become pregnant or father a child, you must use reliable birth control during treatment and for 2 months after venetoclax (and follow sperm donation rules if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial tests a combination of venetoclax with liposome chemotherapy (daunorubicin and cytarabine) for adults with acute myeloid leukemia (AML) that is back after treatment or not responding, and for some newly diagnosed cases. It aims to shrink leukemia and help more people achieve remission.
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
This trial tests a combination of two targeted drugs (tagraxofusp and venetoclax) for people with a rare blood cancer called BPDCN who have not been treated before. The goal is to see if this combination is safe and effective as a first treatment.
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
Hear when a new Blastic Plasmacytoid Dendritic Cell Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.